Format

Send to

Choose Destination
See comment in PubMed Commons below
Bioorg Med Chem Lett. 2013 May 15;23(10):2844-52. doi: 10.1016/j.bmcl.2013.03.028. Epub 2013 Mar 18.

Learning from our mistakes: the 'unknown knowns' in fragment screening.

Author information

1
Vernalis Ltd., Granta Park, Great Abington, Cambridge CB21 6GB, UK. b.davis@vernalis.com

Abstract

In the past 15 years, fragment-based lead discovery (FBLD) has been adopted widely throughout academia and industry. The approach entails discovering very small molecular fragments and growing, merging, or linking them to produce drug leads. Because the affinities of the initial fragments are often low, detection methods are pushed to their limits, leading to a variety of artifacts, false positives, and false negatives that too often go unrecognized. This Digest discusses some of these problems and offers suggestions to avoid them. Although the primary focus is on FBLD, many of the lessons also apply to more established approaches such as high-throughput screening.

PMID:
23562240
DOI:
10.1016/j.bmcl.2013.03.028
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center